Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB

    Two Marketed CNS Products With U.S. Revenues of $20 Million

    Two FDA Approved but Unlaunched Products

    DUBLIN, Jan. 9 /CNW/ - Azur Pharma Limited ("Azur Pharma") today
announced that it licensed the exclusive U.S. marketing rights for Niravam(R)
(alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa
orally disintegrating tablets), Kemstro(TM) (baclofen orally disintegrating
tablets) and Fluxid(TM) (famotidine orally disintegrating tablets) from UCB
(Euronext: UCB). Financial terms were not disclosed.
    Niravam, Parcopa and Kemstro are central nervous system ("CNS") products.
Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the
management of severely ill schizophrenic patients who fail to respond
adequately to standard schizophrenia drug treatments. FazaClo is supplied as
an innovative orally disintegrating tablet that uses proprietary formulation
technologies licensed from CIMA Labs Inc. ("CIMA"), a subsidiary of Cephalon
    Mr Seamus Mulligan, Chairman and Chief Executive of Azur stated, "We are
pleased to add these valuable products to our portfolio. In particular,
Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and
are consistent with our approach of improving our products through the
application of value added drug delivery technologies."
    Niravam and Parcopa have been commercially available in the U.S. since
2005 and 2004, respectively. There is one approved generic competitor to
Parcopa. Two ANDAs to Niravam have been filed with the FDA. Kemstro and Fluxid
are both FDA approved but not yet commercially available in the U.S.

    About Azur Pharma

    Azur is a privately held pharmaceutical company dedicated to enhancing
patients' lives by developing and marketing pharmaceutical products in
specialist therapeutic areas. Azur's strategy is to identify, evaluate,
selectively acquire and enhance the value of late stage development and
approved pharmaceutical products. (Website: )

For further information:

For further information: Mr. Ray Gordon, MRPA Kinman Communications,
Telephone: +353-1-7038619 / +353-87-2417373, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890